About this scholarly article

Poster Presentations - FRI0588 Interim results of a phase 2 study of XMAB®5871, a reversible B cell inhibitor, in IGG4-related disease by Stone, JH; Wallace, ZS; Perugino, CA; Fernandes, AD; Patel, PS; Foster, PA; Zack, DJ is a scholarly article available to read on EtoBox.

Author

Stone, JH; Wallace, ZS; Perugino, CA; Fernandes, AD; Patel, PS; Foster, PA; Zack, DJ

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Published

2017

Language

EN